Safety and efficacy of antiplatelet/anticoagulation regimens after Viabahn stent graft treatment for femoropopliteal occlusive disease

Journal of Vascular Surgery

Volumn 61, Issue 6, 2015, Pages 1479-1488

  Ullery, Brant W ^a   Tran, Kenneth ^a   Itoga, Nathan ^a   Casey, Kevin ^a   Dalman, Ronald L ^a   Lee, Jason T ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ADD ON THERAPY; AGED; ANGIOGRAPHY; ANTICOAGULANT THERAPY; ARTERY GRAFT; ARTERY PROSTHESIS; BLEEDING; BLOOD CLOT LYSIS; BLOOD TRANSFUSION; CLAUDICATION; CLINICAL EVALUATION; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CRITICAL LIMB ISCHEMIA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEMOROPOPLITEAL OCCLUSIVE DISEASE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GRAFT FAILURE; GRAFT OCCLUSION; GRAFT PATENCY; HUMAN; IN-STENT RESTENOSIS; INTERNATIONAL NORMALIZED RATIO; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POSTOPERATIVE CARE; PRIORITY JOURNAL; REOPERATION; RETROSPECTIVE STUDY; RISK FACTOR; TOBACCO USE; TREATMENT DURATION; ADVERSE EFFECTS; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL TRANSPLANTATION; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; DEVICES; DISEASE FREE SURVIVAL; DRUG COMBINATION; ENDOVASCULAR SURGERY; FEMORAL ARTERY; GRAFT OCCLUSION, VASCULAR; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROPORTIONAL HAZARDS MODEL; PROSTHESIS; RADIOGRAPHY; STENOSIS, OCCLUSION AND OBSTRUCTION; STENT; THROMBOSIS; TIME; TREATMENT OUTCOME; UNITED STATES; VASCULAR PATENCY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CALIFORNIA; CHI-SQUARE DISTRIBUTION; CONSTRICTION, PATHOLOGIC; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; ENDOVASCULAR PROCEDURES; FEMORAL ARTERY; GRAFT OCCLUSION, VASCULAR; HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; POPLITEAL ARTERY; PROPORTIONAL HAZARDS MODELS; PROSTHESIS DESIGN; RETROSPECTIVE STUDIES; RISK FACTORS; STENTS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 84929709519     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2014.12.062     Document Type: Conference Paper

References (18)

1. R. Virmani, F.D. Kolodgie, M.D. Dake, J.H. Silver, R.M. Jones, and M. Jenkins Histopathologic evaluation of an expanded polytetrafluoroethylene-nitinol stent endoprosthesis in canine iliofemoral arteries J Vasc Interv Radiol 10 1999 445 456
2. M.A. Golden, S.R. Hanson, T.R. Kirkman, P.A. Schneider, and A.W. Clowes Healing of polytetrafluoroethylene arterial grafts is influenced by graft porosity J Vasc Surg 11 1990 838 844
3. G. Pedersen, E. Laxdal, V. Ellensen, T. Jonung, and E. Mattsson Improved patency and reduced intimal hyperplasia in PTFE grafts with luminal immobilized heparin compared with standard PTFE grafts at six months in a sheep model J Cardiovasc Surg (Torino) 51 2010 443 448
4. J. Lammer, T. Zeller, K.A. Hausegger, P.J. Schaefer, M. Gschwendtner, and S. Mueller-Huelsbeck Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease) J Am Coll Cardiol 62 2013 1320 1327
5. S.R. Mehta, S. Yusuf, R.J. Peters, M.E. Bertrand, B.S. Lewis, and M.K. Natarajan Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
6. S.R. Steinhubl, P.B. Berger, J.T. Mann III, E.T. Fry, A. DeLago, and C. Wilmer Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA 288 2002 2411 2420
7. L. Norgren, W.R. Hiatt, J.A. Dormandy, M.R. Nehler, K.A. Harris, and F.G. Fowkes Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) J Vasc Surg 45 2007 S5 67
8. K. Ouriel, R.J. Fowl, M.G. Davies, T.L. Forbes, R.P. Gambhir, and M.A. Ricci Disease-specific guidelines for reporting adverse events for peripheral vascular medical devices J Vasc Surg 60 2014 212 225
9. M. Monaco, L. Di Tommaso, G.B. Pinna, S. Lillo, V. Schiavone, and P. Stassano Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients J Vasc Surg 56 2012 96 105
10. Warfarin Antiplatelet Vascular Evaluation Trial Investigators S. Anand, S. Yusuf, C. Xie, J. Pogue, and J. Eikelboom Oral anticoagulant and antiplatelet therapy and peripheral artery disease N Engl J Med 357 2007 217 227
11. M.T. Allemang, R.R. Rajani, P.R. Nelson, A. Hingorani, and V.S. Kashyap Prescribing patterns of antiplatelet agents are highly variable after lower extremity endovascular procedures Ann Vasc Surg 27 2013 62 67
12. P.J. Geraghty, M.W. Mewissen, M.R. Jaff, and G.M. Ansel Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease J Vasc Surg 58 2013 386 395
13. K. McQuade, D. Gable, G. Pearl, B. Theune, and S. Black Four-year randomized prospective comparison of percutaneous ePTFE/nitinol self-expanding stent graft versus prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease J Vasc Surg 52 2010 584 590
14. A.F. Jebran, A.F. Popov, D. Zenker, C. Bireta, M. Friedrich, and B.C. Danner Is there an alternative to the surgical above-knee bypass in treatment of superficial femoral artery disease? Experiences with Viabahn stent graft Vasc Endovascular Surg 47 2013 502 506
15. M. Fischer, C. Schwabe, and K.L. Schulte Value of the Hemobahn/Viabahn endoprosthesis in the treatment of long chronic lesions of the superficial femoral artery: 6 years of experience J Endovasc Ther 13 2006 281 290
16. P.C. Johnston, S.M. Vartanian, S.J. Runge, J. Hiramoto, C.M. Eichler, and C.D. Owens Risk factors for clinical failure after stent graft treatment for femoropopliteal occlusive disease J Vasc Surg 56 2012 998 1006
17. R.R. Saxon, A. Chervu, P.A. Jones, T.K. Bajwa, D.R. Gable, and P.A. Soukas Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial J Vasc Interv Radiol 24 2013 165 173
18. B.D. Suckow, L.W. Kraiss, D.H. Stone, A. Schanzer, D.J. Bertges, and D.T. Baril Comparison of graft patency, limb salvage, and antithrombotic therapy between prosthetic and autogenous below-knee bypass for critical limb ischemia Ann Vasc Surg 27 2013 1134 1145